Roche puts up $125M to expand SQZ cell therapy pact

Roche has committed $125 million in upfront and near-term payments to expand its partnership with SQZ Biotechnologies. The revised deal sets Roche up to work with SQZ on antigen-presenting cells designed to trigger killer T cell attacks against tumors.